TJPC(SH:600488) Xin Lang Cai Jing·2025-10-29 01:34Core Insights - Tianjin Pharmaceutical Industry Co., Ltd. (600488.SH) reported a total operating revenue of 2.232 billion yuan for Q3 2025, ranking 28th among disclosed peers, which represents a decrease of 341 million yuan or 13.24% year-on-year [1] - The net profit attributable to shareholders was 69.54 million yuan, ranking 54th among peers, down by 117 million yuan or 62.75% compared to the same period last year [1] - The net cash flow from operating activities was 33.39 million yuan, ranking 65th among peers, a decrease of 421 million yuan or 92.65% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 32.19%, ranking 51st among peers, down by 1.79 percentage points from the previous quarter and 3.42 percentage points from the same period last year [3] - The latest gross profit margin is 40.76%, ranking 52nd among peers, a decrease of 0.95 percentage points from the previous quarter and 3.67 percentage points year-on-year [3] - The latest return on equity (ROE) is 2.30%, ranking 61st among peers, down by 3.82 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.06 yuan, ranking 63rd among peers, a decrease of 0.11 yuan or 62.57% year-on-year [3] - The latest total asset turnover ratio is 0.39 times, ranking 24th among peers, a decrease of 0.03 times or 8.00% year-on-year [3] - The latest inventory turnover ratio is 2.07 times, ranking 35th among peers, an increase of 0.13 times or 6.94% year-on-year, marking two consecutive years of growth [3] Shareholder Information - The number of shareholders is 38,400, with the top ten shareholders holding 651 million shares, accounting for 59.64% of the total share capital [3] - The largest shareholder is Tianjin Pharmaceutical Group Co., Ltd., holding 507 million shares [3]